Jump Financial, LLC Bluebird Bio, Inc. Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	SELL	$3.02 - $4.05 $607,016 - $814,045	-200,999 Reduced 90.43%	21,261 $64,000
Q3 2023 Nov 07, 2023	SELL	$3.02 - $4.05 $607,016 - $814,045	-200,999 Reduced 90.43%	21,261 $64,000
Q2 2023 Oct 21, 2024	BUY	$2.79 - $5.03 $552,858 - $996,729	198,157 Added 822.13%	222,260 $731,000
Q2 2023 Aug 07, 2023	BUY	$2.79 - $5.03 $552,858 - $996,729	198,157 Added 822.13%	222,260 $731,000
Q1 2023 Oct 21, 2024	BUY	$3.14 - $8.22 $75,683 - $198,126	24,103 New	24,103 $76,000
Q1 2023 May 03, 2023	BUY	$3.14 - $8.22 $75,683 - $198,126	24,103 New	24,103 $76,000
Q2 2022 Aug 09, 2022	SELL	$2.94 - $5.23 $116,541 - $207,317	-39,640 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.07 - $10.6 $161,334 - $420,184	39,640 New	39,640 $193,000
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $210,188 - $392,700	-18,700 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.04 - $22.09 $337,348 - $413,083	18,700 New	18,700 $598,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.